INFECTION AND BIOFILM
A CHALLENGE IN WOUND HEALING
While surgical debridement is accepted as the gold standard intervention to promote wound healing, bacterial biofilm can resist debridement and act as a resistance reservoir, leading to considerable delays in wound healing.
DEBRICHEM® IS A NEW, DISRUPTIVE AND HIGHLY EFFECTIVE METHOD TO ELIMINATE BIOFILM AND INFECTION IN A SINGLE 60-SECOND APPLICATION.
ELEVATE YOUR WOUND CARE PORTFOLIO
WITH DEBRICHEM®
DEBRICHEM® is a unique product capable of solving an urgent medical need fast.
GROWING GLOBAL DEMAND
A shocking statistic reveals that 2% of the global population currently lives with chronic wounds.
This number is expected to rise by another 2% in the next decade.
Factors like diabetes, obesity, and an aging population contribute to the surge in hard-to-heal wounds.
This significantly impacts the Global Wound Care Market, forecasted to grow at a CAGR of 4.61% from 2023 to 2030.
In 2022, the market stood at USD 20.18 billion and is anticipated to reach USD 30.52 billion by 2030.
SAVE TIME TO HEALTHCARE PROFESSIONALS
DEBRICHEM® stands out as a groundbreaking product designed to eliminate biofilm and infection, in a one single 60-second application.
In >90% of cases, granulation is achieved after one-single DEBRICHEM® application, saving time during the treatment process and expediting wound healing soltions.
ADDRESSING URGENT CALL
FOR INFECTION SOLUTIONS
Global healthcare demands urgent, efficient solutions to prevent and treat infections.
Infections are surging and are more persistent due to anti-microbial resistance, so the necessity for impactful solution becomes increasingly apparent.
DEBRICHEM® meets this need with its unparalleled efficacy to eliminate infection in hard-to heal wounds in one-single 60-second application.
